intramuscular interferon beta-1a in relapsing-remitting MS
The Multiple sclerosis collaborative research group study was a double-blind, randomised, placebo-controlled trial of the efficacy of interferon beta-1a in mild relapsing-remitting multiple sclerosis.
Patients had mild multiple sclerosis (EDSS scores 1.0-3.5).
The treatment arm received 30 mcg of interferon beta-1a intramuscularly once per week for 1-2 years.
- 1) Jacobs, LD, Cookfair, DL, Rudick, RA, at al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol, 39, 285-94
Last reviewed 01/2018